Short answer · Medically reviewed summary · Last updated: 2026-05-08
Factor XIII deficiency is a rare, inherited bleeding disorder first clinically described in 1960 by Dr. Laszlo Duckert, who identified the condition in a patient with a lifelong history of impaired wound healing.
What is the history of Factor XIII Deficiency?
History of Factor XIII Deficiency: when and how it was discovered, and the milestones in research since, medically reviewed.
Factor XIII deficiency is a rare, inherited bleeding disorder first clinically described in 1960 by Dr. Laszlo Duckert, who identified the condition in a patient with a lifelong history of impaired wound healing. Since its discovery, medical understanding of Factor XIII deficiency has evolved from a mysterious "hemorrhagic diathesis" to a well-characterized condition managed through targeted protein replacement therapies.
When was Factor XIII deficiency first identified?
While physicians had long observed patients with unexplained bleeding, the specific nature of Factor XIII deficiency was not elucidated until the mid-20th century. In 1960, Dr. Laszlo Duckert and his colleagues in Switzerland published the landmark report of a patient who suffered from delayed wound healing and intracranial hemorrhage. This discovery provided the first concrete link between a specific clotting factor deficiency and the clinical symptoms previously labeled as idiopathic.
How has the understanding of Factor XIII deficiency evolved?
Early researchers initially struggled to diagnose Factor XIII deficiency because standard coagulation tests, such as the Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT), return normal results in these patients. It was not until the development of the urea solubility test—which detects the failure of a clot to remain stable in a urea solution—that clinicians could reliably identify the condition. Modern molecular genetics have since allowed us to pinpoint specific mutations in the F13A1 or F13B genes that cause Factor XIII deficiency.
What are the major milestones in treatment development?
The management of Factor XIII deficiency has transformed significantly over the last six decades:
- 1960s-1970s: Reliance on fresh frozen plasma (FFP) or cryoprecipitate, which carried risks of viral transmission and fluid overload.
- 1990s: Development of plasma-derived Factor XIII concentrates, offering a more standardized and safer dosing profile.
- 2010s: Approval of recombinant Factor XIII subunits, which eliminated the need for human-derived plasma products and reduced the risk of transfusion-transmitted infections.
How has patient advocacy shaped the landscape?
Historically, the rarity of Factor XIII deficiency left many patients feeling isolated. Today, global platforms like DiseaseMaps.org allow individuals to connect, sharing personal experiences that complement clinical data. This collective voice has been instrumental in raising awareness among hematologists, ensuring that Factor XIII deficiency is considered in cases of unexplained spontaneous bleeding or recurrent miscarriage.
Next steps
- Consult a hematologist specializing in rare coagulation disorders for personalized management.
- Connect with the 5 members of the DiseaseMaps.org community living with Factor XIII deficiency to share support.
- Register with a national hemophilia or rare bleeding disorder foundation to stay informed about clinical research.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.
References
- Orphanet: Factor XIII deficiency (ORPHA:333)
- NIH GARD: Factor XIII deficiency summary
- OMIM: Coagulation Factor XIII Deficiency (Entry #613225)
- World Federation of Hemophilia (WFH) Guidelines on Rare Bleeding Disorders
